All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @made_to_outlast_bflo on Instagram · 56s|Watch on Instagram
Full video transcriptClick to expand

Auto-generated transcript of @made_to_outlast_bflo's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Here are five things you didn't know about AOD-9604.
  2. 0:04First, pharmaceutical executives secretly used it during merger talks,
  3. 0:08losing 40 pounds in 40 days while gaining 12 pounds of pure muscle.
  4. 0:13Second, Olympic weightlifters dropped entire weight classes while maintaining their lifts,
  5. 0:19achieving impossible body recomposition that broke every known rule.
  6. 0:24Third, tech billionaires eliminated their need for sleep and food
  7. 0:29during 72-hour coding marathons through metabolic optimization.
  8. 0:34Fourth, underground fitness influencers reached body fat below 3%
  9. 0:39while maintaining perfect health markers and preserving all lean tissue.
  10. 0:43Fifth, specific protocols create permanent metabolic changes
  11. 0:47that make obesity physically impossible by targeting fat cells directly.
  12. 0:52This fragment rewrites human physiology.

@made_to_outlast_bflo's AOD9604 claims need context

Made To Outlast

Instagram creator

5.0K viewsView on Instagram

Quick answer

AOD9604 is a synthetic C-terminal fragment of human growth hormone studied for obesity that failed to demonstrate statistically significant weight loss versus placebo in Phase 3 human trials, resulting in no regulatory approval in any jurisdiction. The creator's claims, including 40 pounds of fat loss in 40 days, simultaneous 12-pound muscle gain, and permanent adipocyte elimination, describe outcomes that are physiologically impossible and unsupported by any published human data. Compounded AOD9604 exists in gray-market peptide channels but carries no approved indication, no standardized dosing evidence, and is prohibited by WADA in competitive sport contexts.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @made_to_outlast_bflo's AOD9604 claims need context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@made_to_outlast_bflo's AOD9604 claims need context should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@made_to_outlast_bflo's AOD9604 claims need context" from Made To Outlast. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: AOD9604 is a synthetic C-terminal fragment of human growth hormone studied for obesity that failed to demonstrate statistically significant weight loss versus placebo in Phase 3 human trials, resulting in no regulatory approval in any jurisdiction.

The reason this review is not generic is the source wording and the canonical claim label "peptides all the fat loss of hgh none of the insulin issues." In this clip, the useful excerpt is: "Here are five things you didn't know about AOD-9604." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Animal data on lipolysis is real but limited: Rodent studies (Heffernan et al.
People who land here are usually comparing the Peptide social video fact-checks claim with aod9604, hgh, and metabolism.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

AOD9604 is a synthetic C-terminal fragment of human growth hormone studied for obesity that failed to demonstrate statistically significant weight loss versus placebo in Phase 3 human trials, resulting in no regulatory approval in any jurisdiction.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • AOD9604 is a synthetic C-terminal fragment of human growth hormone studied for obesity that failed to demonstrate statistically significant weight loss versus placebo in Phase 3 human trials, resulting in no regulatory approval in any jurisdiction. The creator's claims, including 40 pounds of fat loss in 40 days, simultaneous 12-pound muscle gain, and permanent adipocyte elimination, describe outcomes that are physiologically impossible and unsupported by any published human data. Compounded AOD9604 exists in gray-market peptide channels but carries no approved indication, no standardized dosing evidence, and is prohibited by WADA in competitive sport contexts.
  • AOD9604 failed Phase 3 clinical trials for obesity: Metabolic Pharmaceuticals' human trials showed no statistically significant weight loss versus placebo, and the compound has no FDA or TGA approval for any indication.
  • Animal data on lipolysis is real but limited: Rodent studies (Heffernan et al., 2001) showed AOD9604 stimulated fat breakdown without affecting IGF-1, which is why researchers were interested. Human translation of that signal has not been confirmed.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • AOD9604 failed Phase 3 clinical trials for obesity: Metabolic Pharmaceuticals' human trials showed no statistically significant weight loss versus placebo, and the compound has no FDA or TGA approval for any indication.
  • Animal data on lipolysis is real but limited: Rodent studies (Heffernan et al., 2001) showed AOD9604 stimulated fat breakdown without affecting IGF-1, which is why researchers were interested. Human translation of that signal has not been confirmed.
  • Losing 40 pounds in 40 days is not biohacking, it's a medical crisis: That pace of loss requires a caloric deficit impossible to sustain safely and is not associated with any compound, peptide, or drug in the clinical literature.
  • AOD9604 is prohibited by WADA: Any claim involving Olympic athletes using this compound for competition ignores that it appears on the World Anti-Doping Agency prohibited list.
  • Compounded AOD9604 is not pharmaceutical-grade: Compounded peptide preparations are not equivalent to the investigational compound tested in clinical trials, and no compounded version carries an approved therapeutic indication.
  • The 'permanent fat cell elimination' claim has no mechanistic basis: Adipocyte biology does not work this way. Fat cells can shrink but the evidence that AOD9604 permanently eliminates them in humans does not exist in peer-reviewed literature.
  • A DM-based 'protocol' from an Instagram account is not medical advice: Regulated telehealth requires licensed clinicians, lab review, and evidence-based decision-making. Anonymous peptide protocols shared via comment section do not meet that standard.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @made_to_outlast_bflo actually say?

The creator made five specific claims about AOD9604, and every single one of them is either fabricated, physically impossible, or completely unsupported by any published research. These weren't exaggerations of real findings. They were invented anecdotes dressed up in scientific-sounding language.

Specifically, the video claims that unnamed pharmaceutical executives lost "40 pounds in 40 days while gaining 12 pounds of pure muscle," that Olympic weightlifters achieved "impossible body recomposition that broke every known rule," that tech billionaires "eliminated their need for sleep and food," that unnamed influencers reached "body fat below 3%" while staying healthy, and that AOD9604 creates "permanent metabolic changes that make obesity physically impossible." The transcript closes with the claim that this peptide "rewrites human physiology." None of these claims reference a study, a trial, or a named individual. That's not an oversight. That's a red flag.

Does the science back this up?

No. The actual clinical research on AOD9604 is thin, dated, and failed at the regulatory finish line. What exists is interesting in theory but nowhere near what this video implies.

AOD9604 is a synthetic peptide derived from amino acids 176 to 191 of human growth hormone. Early animal studies, particularly work published by Heffernan et al. in the early 2000s, showed promise for fat metabolism in obese rodent models. The peptide appeared to stimulate lipolysis without the insulin-disrupting effects of full HGH. That part is real science. But when Metabolic Pharmaceuticals ran Phase 2b and Phase 3 clinical trials in humans for obesity treatment, the drug failed to show statistically significant weight loss compared to placebo. The FDA never approved it. The Australian Therapeutic Goods Administration never approved it either. A 2014 review published in the journal Growth Hormone and IGF Research confirmed the compound's safety profile but could not confirm meaningful efficacy in humans at tested doses. Losing 40 pounds in 40 days would require a caloric deficit of approximately 3,500 calories per day sustained for 40 days. That is not a metabolic optimization story. That is a medical emergency.

What did they get wrong (or right)?

They got one thing directionally right and everything else badly wrong.

The directional truth is that AOD9604 was indeed designed to separate the fat-metabolism signal of HGH from its growth-promoting and insulin-disrupting effects. That's the legitimate scientific hypothesis behind the compound. Early in vitro and animal data suggested it could stimulate lipolysis and inhibit lipogenesis without affecting IGF-1 levels. That's a real distinction from full-spectrum HGH, and it's why researchers were interested in the first place.

But claiming it "rewrites human physiology" or that it makes "obesity physically impossible" through "permanent metabolic changes" is not an extrapolation of that science. It's a fabrication. There is no published mechanism by which AOD9604 permanently alters adipocyte biology. Fat cells don't get deleted. The idea that unnamed executives lost 40 pounds of fat while gaining 12 pounds of muscle simultaneously, in 40 days, contradicts basic energy balance physiology and the known limits of muscle protein synthesis, which tops out around 0.5 pounds per week under optimal conditions even with anabolic support. Reaching 3% body fat while maintaining "perfect health markers" ignores that essential fat for male physiology is generally cited as 2 to 5 percent, and that the lower bound of that range is associated with organ stress, not peak health.

What should you actually know?

AOD9604 is a research peptide with a plausible mechanism, a failed drug approval history, and zero approved human indications as of 2024. That's the honest summary.

If you're curious about peptides for metabolic health, the conversation worth having is with a licensed clinician who can review your labs, your history, and the actual evidence base. What you should not do is DM a stranger on Instagram for a "protocol" based on stories about anonymous billionaires. The creator's framing, including phrases like "biological scalpel" and claims about eliminating the need for sleep and food, borrows the aesthetic of precision medicine to sell something that has no clinical approval and no verified human outcome data behind these specific claims.

AOD9604 is also on WADA's prohibited list, which means the Olympic weightlifter story is doubly implausible: the scenario described would require both physiological miracles and the absence of drug testing. Compounded versions of AOD9604 are available in some markets, but compounded peptides are not equivalent to pharmaceutical-grade investigational compounds, and none of them carry an approved indication for fat loss. Anyone telling you otherwise is not giving you a medical opinion. They're selling you something.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Made To Outlast · Instagram creator

5.0K views on this video

All the fat loss of HGH. None of the insulin issues. 🧬 🔥 Comment “LEAN” and I’ll send you the breakdown of the AOD9604 protocol. AOD9604 isn’t just another "fat burner"—it’s a precise biological

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about aod9604 failed phase 3 clinical trials for obesity: metabolic pharmaceuticals'?

AOD9604 failed Phase 3 clinical trials for obesity: Metabolic Pharmaceuticals' human trials showed no statistically significant weight loss versus placebo, and the compound has no FDA or TGA approval for any indication.

What does the video say about animal data on lipolysis?

Animal data on lipolysis is real but limited: Rodent studies (Heffernan et al., 2001) showed AOD9604 stimulated fat breakdown without affecting IGF-1, which is why researchers were interested. Human translation of that signal has not been confirmed.

What does the video say about losing 40 pounds in 40 days?

Losing 40 pounds in 40 days is not biohacking, it's a medical crisis: That pace of loss requires a caloric deficit impossible to sustain safely and is not associated with any compound, peptide, or drug in the clinical literature.

What does the video say about aod9604?

AOD9604 is prohibited by WADA: Any claim involving Olympic athletes using this compound for competition ignores that it appears on the World Anti-Doping Agency prohibited list.

What does the video say about compounded aod9604?

Compounded AOD9604 is not pharmaceutical-grade: Compounded peptide preparations are not equivalent to the investigational compound tested in clinical trials, and no compounded version carries an approved therapeutic indication.

What does the video say about the 'permanent fat cell elimination' claim has no mechanistic basis:?

The 'permanent fat cell elimination' claim has no mechanistic basis: Adipocyte biology does not work this way. Fat cells can shrink but the evidence that AOD9604 permanently eliminates them in humans does not exist in peer-reviewed literature.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Made To Outlast, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.